Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis

Hong Ren; Li Lin; Pingyan Shen; Xiao Li; Jingyuan Xie; Xiaoxia Pan; Wen Zhang; Nan Chen

doi:10.18632/oncotarget.21833

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers: Immunology:

Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis

Hong Ren _, Li Lin, Pingyan Shen, Xiao Li, Jingyuan Xie, Xiaoxia Pan, Wen Zhang and Nan Chen

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:93438-93443. https://doi.org/10.18632/oncotarget.21833

Metrics: PDF 2028 views | HTML 3219 views | ?

Abstract

Hong Ren1, Li Lin1, Pingyan Shen1, Xiao Li1, Jingyuan Xie1, Xiaoxia Pan1, Wen Zhang1 and Nan Chen1

1 Department of Nephrology, Institute of Nephrology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Correspondence to:

Nan Chen, email:

Keywords: rituximab; steroid-dependent; refractory FSGS; refractory MCD; clinical study, Immunology and Microbiology Section; Immune response; Immunity

Received: September 02, 2016 Accepted: September 05, 2017 Published: October 15, 2017

Abstract

Rituximab (RTX) may benefit patients with glomerular disease who suffer from focal segmental glomerular sclerosis (FSGS) or minimal change disease (MCD). Here, we have described our experience treating 6 FSGS and 9 MCD patients with steroid-dependent/refractory nephrotic syndrome (NS) with RTX. Patients received RTX (375 mg/m2) intravenously on days 1, 8, 23, and 29. During a median follow-up of 8 months (range, 3-36 months) after RTX administration, all patients achieved complete or partial remission. Relapses decreased by approximately 30-fold compared with the year preceding RTX treatment, and an 89.27% reduction in proteinuria was observed. Furthermore, RTX treatment could decrease medical costs by 76.52% compared with the costs associated with the long-term use (for 12-13 months) of steroids and immunosuppressive drugs.

In conclusion, RTX treatment was safe and effective for patients with refractory FSGS or MCD.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21833

Publication Alerts

Research Papers: Immunology:

Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis

Abstract